European Generics Need To Climb Into Niches, Huddle Together For Growth
Executive Summary
The current situation for Europe’s generic medicines manufacturers is at best uncomfortable due to significant pricing pressures and increasing competition, but the reality is that it is likely to get far worse.
You may also be interested in...
Generics Manufacturing, Stockpiling Before IP Expiries Could Boost EU
If generics firms were permitted to manufacture and stockpile products ahead of IP expiries, it’s estimated they could add almost €4.5 billion ($6.3 billion) to the EU economy over nine years.
Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.